Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 134


In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coli.

Ma Y, Yu YZ, Zhu YF, Xu Q, Sun ZW.

Hum Vaccin Immunother. 2013 Nov;9(11):2371-7. Epub 2013 Jul 23.


Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.

Abboud N, Casadevall A.

Clin Vaccine Immunol. 2008 Jul;15(7):1115-23. doi: 10.1128/CVI.00015-08. Epub 2008 May 14.


A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.

Gorantala J, Grover S, Goel D, Rahi A, Jayadev Magani SK, Chandra S, Bhatnagar R.

Vaccine. 2011 Jun 15;29(27):4521-33. doi: 10.1016/j.vaccine.2011.03.082. Epub 2011 Apr 17.


Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.

Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr.

Infect Immun. 2007 Aug;75(8):4020-9. Epub 2007 May 14.


Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.

Kelly-Cirino CD, Mantis NJ.

Infect Immun. 2009 Nov;77(11):4859-67. doi: 10.1128/IAI.00117-09. Epub 2009 Aug 24.


Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.

Chi X, Li J, Liu W, Wang X, Yin K, Liu J, Zai X, Li L, Song X, Zhang J, Zhang X, Yin Y, Fu L, Xu J, Yu C, Chen W.

Clin Vaccine Immunol. 2015 May;22(5):553-60. doi: 10.1128/CVI.00792-14. Epub 2015 Mar 18.


Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Williamson ED, Hodgson I, Walker NJ, Topping AW, Duchars MG, Mott JM, Estep J, Lebutt C, Flick-Smith HC, Jones HE, Li H, Quinn CP.

Infect Immun. 2005 Sep;73(9):5978-87.


Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Lu H, Catania J, Baranji K, Feng J, Gu M, Lathey J, Sweeny D, Sanford H, Sapru K, Patamawenu T, Chen JH, Ng A, Fesseha Z, Kluepfel-Stahl S, Minang J, Alleva D.

Clin Vaccine Immunol. 2013 Jul;20(7):986-97. doi: 10.1128/CVI.00046-13. Epub 2013 May 1.


Comparison of three anthrax toxin neutralization assays.

Ngundi MM, Meade BD, Lin TL, Tang WJ, Burns DL.

Clin Vaccine Immunol. 2010 Jun;17(6):895-903. doi: 10.1128/CVI.00513-09. Epub 2010 Apr 7.


Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine.

Gorantala J, Grover S, Rahi A, Chaudhary P, Rajwanshi R, Sarin NB, Bhatnagar R.

J Biotechnol. 2014 Apr 20;176:1-10. doi: 10.1016/j.jbiotec.2014.01.033. Epub 2014 Feb 15.


Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.

Clement KH, Rudge TL Jr, Mayfield HJ, Carlton LA, Hester A, Niemuth NA, Sabourin CL, Brys AM, Quinn CP.

Clin Vaccine Immunol. 2010 Nov;17(11):1753-62. doi: 10.1128/CVI.00174-10. Epub 2010 Aug 25.


Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge with Bacillus cereus G9241.

Palmer J, Bell M, Darko C, Barnewall R, Keane-Myers A.

Pathog Dis. 2014 Nov;72(2):138-42. doi: 10.1111/2049-632X.12204. Epub 2014 Sep 19.


The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.

Nguyen ML, Terzyan S, Ballard JD, James JA, Farris AD.

Infect Immun. 2009 Nov;77(11):4714-23. doi: 10.1128/IAI.00749-09. Epub 2009 Aug 31.


Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.

Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR.

J Immunol. 2003 Jun 1;170(11):5636-43.


Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model.

Makam SS, Kingston JJ, Harischandra MS, Batra HV.

Mol Immunol. 2014 May;59(1):91-9. doi: 10.1016/j.molimm.2014.01.012. Epub 2014 Feb 8.


Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL.

Clin Vaccine Immunol. 2012 Sep;19(9):1465-73. doi: 10.1128/CVI.00174-12. Epub 2012 Jul 18.


Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.

Oscherwitz J, Yu F, Jacobs JL, Cease KB.

Clin Vaccine Immunol. 2013 Mar;20(3):341-9. doi: 10.1128/CVI.00612-12. Epub 2013 Jan 2.


Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.

Parreiras PM, Sirota LA, Wagner LD, Menzies SL, Arciniega JL.

Vaccine. 2009 Jul 16;27(33):4537-42. doi: 10.1016/j.vaccine.2009.05.045. Epub 2009 Jun 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk